Recently, the National Intellectual Property Administration released the list of demonstration entities for building a national intellectual property powerhouse from 2025 to 2027. Xuanzhu (Beijing) Medical Technology Co., Ltd., a wholly-owned subsidiary of Xuanzhu Bio, was successfully selected as a candidate for the "National Intellectual Property Demonstration Enterprise" program—a clear recognition of the company's intellectual property efforts by the national intellectual property authority.

The "National Intellectual Property Demonstration Enterprise" title is awarded every three years by the National Intellectual Property Administration through a rigorous process involving voluntary applications, provincial recommendations, document review, expert evaluation, and public announcement. It represents a prestigious honor with significant influence and benchmark status in China's intellectual property sector. Recipient enterprises must demonstrate outstanding performance in intellectual property creation quality, utilization efficiency, protection effectiveness, management capabilities, and service standards, serving as exemplary models for industry innovation and development.
    
As a National High-Tech Enterprise and a Beijing-based "Specialized, Refined, Unique, and Innovative" small and medium-sized enterprise, Xuanzhu (Beijing) has consistently prioritized its intellectual property strategy at the core of its development, employing various specialized approaches to comprehensively protect its intellectual property assets. Its inclusion in the list of National Intellectual Property Demonstration Enterprises represents full recognition of the company's outstanding intellectual property efforts.
    
In the future, Xuanzhu Biotech will continue to increase investment in independent R&D and deepen its efforts in innovative drug development. Simultaneously, it will continuously improve its intellectual property management mechanisms, establish a comprehensive intellectual property protection system across the entire value chain, enhance overall intellectual property governance capabilities, and empower the company's high-quality development.